We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
+40.37%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$224M
AUM Growth
+$59.3M
Cap. Flow
+$4.84M
Cap. Flow %
2.16%
Top 10 Hldgs %
84.52%
Holding
14
New
–
Increased
5
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.7M
2
AMRN
Amarin Corp
AMRN
+$3.66M
3
AXSM icon
Axsome Therapeutics
AXSM
+$2.04M
4
FOLD
Amicus Therapeutics
FOLD
+$2.01M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$1.77M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$4.65M
2
TRIL
Trillium Therapeutics Inc.
TRIL
+$2.07M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$864K
4
NGNE icon
Neurogene
NGNE
+$521K
5
INSM icon
Insmed
INSM
+$237K

Sector Composition

Rank Sector Weight
1 Healthcare 94.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
Acadia Pharmaceuticals
ACAD
$4.38B
$28.4M 12.66%
585,517
-18,000
-3% -$864K
INSM icon
2
Insmed
INSM
$23.5B
$27.8M 12.42%
1,010,797
-10,000
-1% -$237K
ZGNX
3
DELISTED
Zogenix, Inc.
ZGNX
$26.3M 11.71%
971,875
– –
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$22.7M 10.13%
1,505,395
+165,000
+12% +$2.01M
AXSM icon
5
Axsome Therapeutics
AXSM
$11.8B
$17.8M 7.93%
216,098
+26,500
+14% +$2.04M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$2.23B
$16.6M 7.39%
603,890
+112,500
+23% +$3.7M
ALLK
7
DELISTED
Allakos
ALLK
$12.8M 5.73%
178,662
– –
NGNE icon
8
Neurogene
NGNE
$744M
$12.8M 5.7%
38,504
-2,000
-5% -$521K
KPTI icon
9
Karyopharm Therapeutics
KPTI
$216M
$12.4M 5.51%
43,490
+6,000
+16% +$1.77M
TRIL
10
DELISTED
Trillium Therapeutics Inc.
TRIL
$12M 5.35%
1,483,181
-335,000
-18% -$2.07M
ARGX icon
11
argenx
ARGX
$53.8B
$11.4M 5.07%
50,450
-26,188
-34% -$4.65M
AMRN
12
Amarin Corp
AMRN
$292M
$9.71M 4.33%
70,162
+26,576
+61% +$3.66M
ENTA icon
13
Enanta Pharmaceuticals
ENTA
$400M
$8.53M 3.81%
169,949
– –
KNSA icon
14
Kiniksa Pharmaceuticals
KNSA
$4.92B
$5.1M 2.27%
200,125
– –

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q2 2020 Portfolio in Review

As of Q2 2020, Fairmount Funds Management held 14 positions worth $224M, up 36% from $165M the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Trading was light in Q2 2020: portfolio turnover was 0%. Fairmount Funds Management opened no new positions and made no exits, leaving the 14-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier.

  • Fairmount Funds Management added most to Iovance Biotherapeutics in Q2 2020, an estimated $3.7M increase.
  • Fairmount Funds Management's biggest Q2 2020 reduction was argenx, cutting an estimated $4.65M.
  • Fairmount Funds Management's ten largest holdings make up 85% of its $224M portfolio in Q2 2020.
  • Fairmount Funds Management opened 0 new positions and closed 0 in Q2 2020.
  • Fairmount Funds Management's portfolio value rose 36% quarter-over-quarter to $224M.

Based on Fairmount Funds Management's 13F filing for Q2 2020, filed 4 Aug 2020.